CONTRAINDICATIONS
NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

...CONTINUED BELOW

NUCALA reduced patients' daily oral corticosteroid (OCS) dose while maintaining asthma control (SIRIUS study)

Performed as a sensitivity analysis to the primary endpoint; results considered exploratory."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"8
† 
Results are descriptive only; statistical significance cannot be inferred."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"8

 

Study description: SIRIUS"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"8 (Trial 3)

A 24-week study that evaluated the effect of NUCALA compared with placebo.

Primary endpoint: Percent reduction in daily OCS dose (Weeks 20 to 24) while maintaining asthma control.

View full study design >

   818427R0 April 2017